Related Experiment Videos

An update on the malignant hyperthermia syndrome

H Rosenberg1, J E Fletcher

  • 1Department of Anesthesiology, Hahnemann University, Philadelphia, PA 19102-1192, USA.

Insights

Malignant hyperthermia (MH) is a rare genetic disorder affecting skeletal muscle. Understanding its molecular genetics may lead to better diagnostic tests and treatments for this serious condition.

Area of Science:

  • Pharmacogenetics
  • Skeletal Muscle Physiology
  • Anesthesiology

Background:

  • Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle, inherited differently in humans (autosomal dominant) and swine (recessive).
  • Susceptibility to MH is typically asymptomatic until exposure to specific anesthetic agents like isoflurane, enflurane, or succinylcholine.
  • Exposure triggers a hypermetabolic state, leading to acidosis, muscle rigidity, rhabdomyolysis, and potentially fatal hyperthermia, with mortality rates up to 70% if untreated.

Purpose of the Study:

  • To explore the pathophysiology of malignant hyperthermia, focusing on calcium flux defects in skeletal muscle.
  • To investigate the genetic basis of MH, particularly the role of the ryanodine receptor calcium channel.
  • To highlight the need for improved diagnostic methods and a deeper understanding of MH and related myopathies.

Main Methods:

  • Review of existing literature on malignant hyperthermia genetics and pathophysiology.
  • Comparison of MH inheritance patterns and clinical presentations in humans and swine models.
  • Analysis of the role of specific gene mutations, such as those in the ryanodine receptor, in MH susceptibility.

Main Results:

  • MH pathophysiology involves a defect in skeletal muscle calcium flux.
  • A specific mutation in the ryanodine receptor gene is identified in susceptible swine but is rare in humans.
  • MH is more prevalent in children, who may exhibit paradoxical jaw muscle hypertonia to succinylcholine.

Conclusions:

  • Prompt diagnosis and dantrolene sodium treatment significantly reduce MH mortality to less than 10%.
  • Understanding the molecular genetics of MH is crucial for developing simpler diagnostic tests.
  • Further research into MH genetics can enhance our understanding of this disorder and its relationship to other myopathies.

Related Concept Videos